Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impaired tamoxifen metabolism reduces survival in familial breast cancer patients.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Sept 2008

Newman William G, Hadfield Kristen D, Latif Ayshe, Roberts Stephen A, Shenton Andrew, McHague Christopher, Lalloo Fiona, Howell Sacha, Evans D Gareth

Abstract excerpt

PURPOSE: Tamoxifen has been the mainstay adjuvant hormonal treatment for breast cancer for many years. Conversion of tamoxifen to its active metabolite, endoxifen, is reduced by low activity of the cytochrome P450 enzyme, CYP2D6. We examined the effect of reduced CYP2D6 activity on the response to tamoxifen in patients with familial early-onset breast cancer. EXPERIMENTAL DESIGN: We conducted a case note review...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Estrogen Antagonists

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Survival Analysis

Share to Tamoxifen

Source

Identifiers

PMID: 18794105
DOI: 10.1158/1078-0432.CCR-07-5235

Genes

BRCA2
BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impaired tamoxifen metabolism reduces survival in familial breast cancer patients.PMID 18794105Read ↗

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.Semantic proximity Read ↗

Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast CancerSemantic proximity Read ↗

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.Semantic proximity Read ↗

The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer.Semantic proximity Read ↗

CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.Semantic proximity Read ↗

CYP2D6 testing in breast cancer: ready for prime time?Semantic proximity Read ↗

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.Semantic proximity Read ↗

A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen.Semantic proximity Read ↗

Pharmacogenomics of tamoxifen therapy.Semantic proximity Read ↗

CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.Semantic proximity Read ↗

CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen.Semantic proximity Read ↗

Early increase in tamoxifen dose in CYP2D6 poor metaboliser breast cancer patients and survival: A propensity score matching analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.